Profile data is unavailable for this security.
About the company
Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
- Revenue in USD (TTM)0.00
- Net income in USD-139.66m
- Incorporated2020
- Employees183.00
- LocationHumacyte Inc2525 East North Carolina Highway 54DURHAM 27713United StatesUSA
- Phone+1 (919) 313-9633
- Fax+1 (302) 655-5049
- Websitehttps://humacyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | 89.04m | -241.08m | 577.76m | 344.00 | -- | 1.66 | -- | 6.49 | -5.27 | -5.27 | 1.93 | 7.06 | 0.1423 | -- | 4.03 | 258,848.80 | -38.52 | -16.75 | -46.55 | -19.08 | 56.78 | 78.27 | -270.74 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| SS Innovations International Inc | 14.41m | -23.68m | 580.51m | 239.00 | -- | 34.18 | -- | 40.29 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 582.30m | 28.00 | -- | 2.01 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Allogene Therapeutics Inc | 65.00k | -279.42m | 585.51m | 232.00 | -- | 1.14 | -- | 9,007.88 | -1.59 | -1.59 | 0.0004 | 2.46 | 0.00009 | -- | -- | 280.17 | -39.41 | -28.46 | -42.15 | -30.21 | -- | -- | -429,881.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 590.26m | 44.00 | -- | 1.75 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 590.69m | 41.00 | -- | 17.53 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 600.08m | 285.00 | -- | 2.50 | -- | 164.81 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Y-mAbs Therapeutics Inc | 86.55m | -24.61m | 611.94m | 100.00 | -- | 6.42 | -- | 7.07 | -0.5618 | -0.5618 | 1.98 | 2.14 | 0.6262 | 1.42 | 4.19 | 865,460.00 | -17.81 | -44.23 | -23.58 | -50.45 | 88.74 | -- | -28.44 | -181.13 | 2.72 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -72.31m | 615.65m | 6.00 | -- | 3.00 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 618.44m | 201.00 | -- | 1.05 | -- | 30.59 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Third Harmonic Bio Inc | 0.00 | -32.74m | 618.93m | 42.00 | -- | 2.39 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Humacyte Inc | 0.00 | -139.66m | 620.63m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Alumis Inc | -100.00bn | -100.00bn | 624.01m | 128.00 | -- | -- | -- | -- | -- | -- | -- | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Exscientia PLC (ADR) | 28.00m | -172.63m | 651.45m | 483.00 | -- | 1.62 | -- | 23.26 | -1.35 | -1.35 | 0.2203 | 3.10 | 0.042 | -- | 26.88 | 57,975.65 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Humacyte Inc's reporting currency: US Dollar USD
14.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.43m | 3.72% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.91m | 3.28% |
| Sio Capital Management LLCas of 31 Mar 2024 | 2.00m | 1.68% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.86m | 1.56% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.21m | 1.02% |
| Monashee Investment Management LLCas of 31 Mar 2024 | 1.00m | 0.84% |
| Teachers Advisors LLCas of 30 Jun 2024 | 943.26k | 0.79% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 600.30k | 0.50% |
| Prescott General Partners LLCas of 31 Mar 2024 | 568.25k | 0.48% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 534.01k | 0.45% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
